Company intelligence / Profile preview

Spitfire Pharma

San Francisco Bay Area, California, United States

Ownership: Private
Development stage: Other

Overview

Spitfire Pharma developed SP-1373, a peptide-based drug, as a product candidate for metabolic diseases; acquired by Altimmune in 2019 and SP-1373 was renamed ALT-801[5].

Therapeutic areas: EndocrinologyGastroenterology
Modalities: PeptidesSmall molecule (peptide drug optimization/improvement)
Industry: Biotech

Partnerships

Velocity Pharmaceutical DevelopmentPresidio Partners

Beyond the preview

Go deeper on Spitfire Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spitfire Pharma.

Explore the full profile